in patients with thyroid cancer (follicular or papillary), injektion with recombinant TSH to increase s-TSH before iodine uptake to detect remaining cancer og recurrence of cancer in patients surgecal treated thyroid cancer MedDRA version: 9.1 Level: LLT Classification code 10033701 Term: Papillary thyroid cancer MedDRA version: 9.1 Level: LLT Classification code 10016935 Term: Follicular thyroid cancer
Conditions
Interventions
Trade Name: thyrogen
Product Name: thyrogen
Pharmaceutical Form: Injection*
Other descriptive name: THYROTROPIN ALFA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number:
Sponsors
dept of endocrinology J 106, herlev Hosptial
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients, surgery treated for thyroid cancer, follicular og papillary. age 18-75yaer Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 75 year old pregnant or lactating women persons not able to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Quality of life related to recombinant TSH treatment compared to no treatment related to iodine uptake, in patient with thyroid cancer (follikcular, papillary). A double blinded, randomized crossover study. ;Secondary Objective: ;Primary end point(s): quality of life evaluated with VAS, SF- 36, Eorts QLC 30 | — |
Countries
Denmark
Outcome results
None listed